p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer

Postnatal Expression of BRAFV600EDoes Not Induce Thyroid Cancer in Mouse Models of Thyroid Papillary Carcinoma

(2013) Mika Shimamura et al.   ENDOCRINOLOGY

BRAF V600E Inhibition in Anaplastic Thyroid Cancer

(2013) Michael H. Rosove et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring BRAFV600E Mutation

(2013) Kevin B. Kim et al.   THYROID

Thyrotropin Signaling Confers More Aggressive Features with Higher Genomic Instability on BRAFV600E-Induced Thyroid Tumors in a Mouse Model

(2013) Florence Orim et al.   THYROID

Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF -Mutant Thyroid Carcinomas

(2013) Cristina Montero-Conde et al.   Cancer Discovery

mTOR Pathway Overactivation in BRAF Mutated Papillary Thyroid Carcinoma

(2012) Alexandra Faustino et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer

(2012) Robert C. Smallridge et al.   THYROID

Mutationally Activated BRAFV600E Elicits Papillary Thyroid Cancer in the Adult Mouse

(2011) R.-P. Charles et al.   CANCER RESEARCH

Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer

(2011) N. Jin et al.   CLINICAL CANCER RESEARCH

Late Intervention with anti-BRAFV600ETherapy Induces Tumor Regression in an Orthotopic Mouse Model of Human Anaplastic Thyroid Cancer

(2011) Matthew A. Nehs et al.   ENDOCRINOLOGY

The Primary Occurrence ofBRAFV600EIs a Rare Clonal Event in Papillary Thyroid Carcinoma

(2011) Anna Guerra et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation

(2011) Debyani Chakravarty et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeted therapies for thyroid tumors

(2011) Steven I Sherman   MODERN PATHOLOGY

Molecular genetics and diagnosis of thyroid cancer

(2011) Yuri E. Nikiforov et al.   Nature Reviews Endocrinology

Progression of BRAF-induced thyroid cancer is associated with epithelial–mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling

(2011) J A Knauf et al.   ONCOGENE

Targeting BRAFV600E with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer

(2011) C. Nucera et al.   ONCOLOGIST

BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis

(2011) Guillaume Gauchotte et al.   PATHOLOGY

Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice

(2011) A. T. Franco et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for BRAF, PIK3CA, and AKT1

(2009) J. C. Ricarte-Filho et al.   CANCER RESEARCH

Targeting the PI3K signaling pathway in cancer

(2009) Kwok-Kin Wong et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer

(2009) David S. Cooper et al.   THYROID

Association ofPTENgene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors

(2008) Peng Hou et al.   CANCER

Phosphatidylinositol 3-Kinase/Akt and Ras/Raf-Mitogen-Activated Protein Kinase Pathway Mutations in Anaplastic Thyroid Cancer

(2007) Libero Santarpia et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM